SCHEMBL342425

SCHEMBL342425

C=C(C)C(=O)Nc1cc[c]cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.58
TDP1 Q9NUW8 3/20 0.51
L3MBTL1 Q9Y468 5/20 0.43
POLB P06746 3/20 0.43
ALDH1A1 P00352 3/20 0.43
RECQL P46063 2/20 0.43
BLM P54132 2/20 0.43
KDM4E B2RXH2 2/20 0.43
BAZ1A Q9NRL2 1/20 0.42
GAA P10253 1/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NAPRT Q6XQN6 1/20 0.38
HSD17B10 Q99714 1/20 0.38
FGFR1 P11362 1/20 0.37
FGFR4 P22455 1/20 0.37
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL439393 0.85 RXFP1 (0.74) RXFP1TDP1L3MBTL1POLBALDH1A1
SCHEMBL3376178 0.80 RXFP1 (0.37) RXFP1TDP1L3MBTL1ALDH1A1KDM4E
SCHEMBL5464327 0.80 F2 (0.41) RXFP1TDP1L3MBTL1ALDH1A1KDM4E
SCHEMBL219147 0.79 KDM4E (0.66) RXFP1TDP1L3MBTL1POLBALDH1A1
SCHEMBL17084525 0.79 RXFP1 (0.67) RXFP1TDP1L3MBTL1POLBALDH1A1
SCHEMBL19602 0.79 SMN1; SMN2 (0.60) TDP1L3MBTL1POLBALDH1A1KDM4E
SCHEMBL3911427 0.78 TDP1 (0.54) RXFP1TDP1L3MBTL1POLBALDH1A1
SCHEMBL124216 0.78 RXFP1 (0.65) RXFP1TDP1L3MBTL1POLBALDH1A1
SCHEMBL959539 0.78 RXFP1 (0.65) RXFP1TDP1L3MBTL1POLBALDH1A1
SCHEMBL9078037 0.77 RXFP1 (0.59) RXFP1TDP1ALDH1A1RECQLHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2915186-B1 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT VERSUM MAT US LLC (US) 2020-10-28 EP claimed
CN-101516896-B Phosphate ester compound, metal salt thereof, dental material, and demtal composition MITSU CHEMICALS INC 2013-06-05 CN claimed
CN-101516896-A Phosphate ester compound, metal salt thereof, dental material, and demtal composition MITSUI CHEMICALS INC (JP) 2009-08-26 CN claimed
JP-8134077-A None JP disclosed
EP-2915186-B1 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT VERSUM MAT US LLC (US) 2020-10-28 EP disclosed
CN-110194877-A A kind of Nanometer composite hydrogel and its preparation method and application 湘潭大学 2019-09-03 CN disclosed
CN-104781909-B It is used to form the solution formula and method of the substrate comprising arsenic dopant 慧盛材料美国有限责任公司 2019-02-05 CN disclosed
CN-109082126-A A kind of hydrogel multi-stage motor and preparation method thereof of glucose responding driving 华南理工大学 2018-12-25 CN disclosed
US-9867884-B2 Vascular delivery systems BEN-GURION UNIVERSITY OF NEGEV RESEARCH & DEVELOPMENT AUTHORITY (IL) 2018-01-16 US disclosed
EP-2274017-B1 E-SELECTIN SPECIFIC VASCULAR DELIVERY SYSTEMS UNIV BEN GURION (IL) 2016-04-13 EP disclosed
EP-2915186-A2 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT Dynaloy, LLC (US) 2015-09-09 EP disclosed
WO-2014071352-A2 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT DYNALOY, LLC (US) 2014-05-08 WO disclosed
US-20140124896-A1 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT DYNALOY, LLC (US) 2014-05-08 US disclosed
CN-101516896-B Phosphate ester compound, metal salt thereof, dental material, and demtal composition MITSU CHEMICALS INC 2013-06-05 CN disclosed
EP-2510023-A1 PHOTOALIGNMENT MATERIALS HAVING IMPROVED ADHESION Transitions Optical, Inc. (US) 2012-10-17 EP disclosed
US-20120014904-A1 VASCULAR DELIVERY SYSTEMS BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) 2012-01-19 US disclosed
WO-2011071794-A1 PHOTOALIGNMENT MATERIALS HAVING IMPROVED ADHESION TRANSITIONS OPTICAL, INC. (US) 2011-06-16 WO disclosed
CN-101516896-A Phosphate ester compound, metal salt thereof, dental material, and demtal composition MITSUI CHEMICALS INC (JP) 2009-08-26 CN disclosed
CN-1790772-A Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device SEIKO EPSON CORP (JP) 2006-06-21 CN disclosed
JP-H08134077-A ANTIBACTERIAL MONOMER AND ITS SYNTHESIS SOGO SHIKA IRYO KENKYUSHO:KK 1996-05-28 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140124896-A1 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT AS3MT, ABL1, ASF1A RXFP1 3652/4885TDP1 209/4885L3MBTL1 1558/4885
US-20120014904-A1 VASCULAR DELIVERY SYSTEMS SELE, SELPLG, SELL RXFP1 2569/4885TDP1 2875/4885L3MBTL1 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.